Anidulafungin in treatment of experimental invasive infection by Candida parapsilosis: In vitro activity, (1→3)-β-D-glucan and mannan serum levels, histopathological findings, and In Vivo efficacy

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 11, 2011, Pages 4985-4989

  Salas, Valentina ^a   Pastor, F Javier ^a   Calvo, Enrique ^a   Mayayo, Emilio ^a   Quindós, Guillermo ^b   Carrillo, Alfonso J ^c   Guarro, Josep ^a  

^a FACULTAT DE MEDICINA I CIÈNCIES DE LA SALUT   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^c Asesoria Cientifica y de Investigacion Aplicada   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

(1-3) BETA DEXTRO GLUCAN; ANIDULAFUNGIN; GLUCAN; MANNAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA PARAPSILOSIS; CANDIDIASIS; FUNGAL STRAIN; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL;

ANIMALS; ANTIFUNGAL AGENTS; BETA-GLUCANS; CANDIDA; CANDIDIASIS; ECHINOCANDINS; KAPLAN-MEIER ESTIMATE; MALE; MANNANS; MICE; MICROBIAL SENSITIVITY TESTS;

EID: 80054707116     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00500-11     Document Type: Article

References (21)

1. Andes, D., et al. 2010. In vivo comparison of the pharmacodynamic targets for echinocandin drugs against Candida species. Antimicrob. Agents Chemother. 54:2497-2506.
2. Barchiesi, F., et al. 2006. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrob. Agents Chemother. 50:2719-2727. (Pubitemid 44198693)
3. Calvo, E., F. J. Pastor, E. Mayayo, V. Salas, and J. Guarro. 2010. In vitro activity and in vivo efficacy of anidulafungin in murine infections by Aspergillus flavus. Antimicrob. Agents Chemother. 55:1290-1292.
4. Cantón, E., A. Espinel-Ingroff, J. Pemán, and L. del Castillo. 2010. In vitro fungicidal activities of echinocandins against Candida metapsilosis, C. orthopsilosis, and C. parapsilosis evaluated by time-kill studies. Antimicrob. Agents Chemother. 54:2194-2197.
5. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard, 3rd ed. Document M27-A3. CLSI, Wayne, PA.
6. Clinical and Laboratory Standards Institute. 2008. Method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline. Document M44-A2. CLSI, Wayne, PA.
7. Espinel-Ingroff. 1998. Comparison of in vitro activities of the new triazole SCH 56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36:2950-2956.
8. Ghannoum, M. A., et al. 2009. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit. Clin. Microbiol. Infect. 15:274-279.
9. Graybill, J. R., R. Bocanegra, L. K. Najvar, D. Loebenberg, and M. F. Luther. 1998. Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression. Antimicrob. Agents Chemother. 42:2467-2473. (Pubitemid 28462881)
10. Kuti, E. L., and J. L. Kuti. 2010. Pharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections. Expert Opin. Drug Metab. Toxicol. 6:1287-1300.
11. Pappas, P. G., et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infections Diseases Society of America. Clin. Infect. Dis. 48:503-535.
12. Pfaller, M. A., et al. 2008. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J. Clin. Microbiol. 46:150-156.
13. Pfaller, M. A., et al. 2005. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J. Clin. Microbiol. 43:5425-5427. (Pubitemid 41612308)
14. Pfaller, M. A., and D. J. Diekema. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-166.
15. Pfaller, M. A., et al. 2011. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretative criteria. Drug Resist. Updat. 14:164-176.
16. Pfaller, M. A., et al. 2005. Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. Antimicrob. Agents Chemother. 49:4795-4797. (Pubitemid 41552623)
17. Pfaller, M. A., G. J. Moet, S. A. Messer, R. N. Jones, and M. Castanheira. 2011. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009. Antimicrob. Agents Chemother. 55:561-566.
18. Pickering, J. W., H. W. Sant, C. A. P. Bowles, W. L. Roberts, and G. L. Woods. 2005. Evaluation of a (1→3)-β-D-glucan assay for diagnosis of invasive fungal infections. J. Clin. Microbiol. 43:5957-5962. (Pubitemid 43100644)
19. Reboli, A. C., et al. 2007. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med. 356:2472-2482. (Pubitemid 46919773)
20. Trofa, D., A. Gácser, and J. D. Nosanchuk. 2008. Candida parapsilosis, an emerging fungal pathogen. Clin. Microbiol. Rev. 21:606-625.
21. van Asbeck, E. C., K. V. Clemons, and D. A. Stevens. 2009. Candida parapsilosis: a review of its epidemiology, pathogenesis, clinical aspects, typing and antimicrobial susceptibility. Crit. Rev. Microbiol. 35:283-309.